首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells
【24h】

Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells

机译:高效液相色谱串联质谱法(LC-MS / MS)定量测定人外周血单个核细胞中10种抗逆转录病毒药物的验证和临床应用

获取原文
获取原文并翻译 | 示例
           

摘要

This paper reports the validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method that allows the quantification of 10 antiretroviral (ARV) drugs in peripheral blood mononuclear cells (PBMCs) using 6 different isotopic internal standards (IS) and its clinical application. PBMCs are isolated from blood by density gradient centrifugation and drugs are extracted with a 60% methanol (MeOH) Solution containing the 6 IS. The cell extract is then injected in the HPLC system and analytes are separated on a Symmetry Shield RP18 2.1 mm x 50 mm column. The different molecules are then detected by MS/MS in electrospray positive or negative ionisation modes and data are recorded using the multiple reaction monitoring (MRM) mode. Calibration curves are constructed in the range of 0.25-125 ng/ml of cell extract by a 1/x(2) weighted quadratic regression. The regression coefficients obtained are always greater than 0.99 and back calculated values always comprised in the range of +/- 15% from their nominal concentration. Mean extraction recoveries are greater than 80% for all analytes and the method is accurate and precise with CV and bias lower than 9.4%. The lower limits of quantification (LLOQ) of the different drugs range from 0.0125 to 0.2 ng/ml of cell extract. This method was successfully applied to a cohort of 98 HIV-infected patients treated with Kaletra (R) (400/100 mg of lopinavir/ritonavir (LPV/RTV) twice a day, n = 48) or with Stocrin (R) (600 mg once a day, n = 50) and has been tested for cellular quantification of tipranavir (TPV) in 2 patients treated with Aptivus (R) (500 mg twice a day). The patients treated by Kaletra (R) showed mean cell-associated concentrations (CC) of 1819.0 and 917.2 ng/ml, for LPV and RTV, respectively. Patients treated with Stocrin (R) showed mean CC of 2388.11 ng/ml while both patients under Aptivus (R) showed TPV CC of 4322.7 and 1078.0 ng/ml, respectively. This method can be used to analyze ARV drug concentrations within the target tissue.
机译:本文报告了液相色谱串联质谱(LC-MS / MS)方法的验证,该方法允许使用6种不同的同位素内标(IS)及其在定量法中对外周血单核细胞(PBMC)中的10种抗逆转录病毒(ARV)药物进行定量临床应用。通过密度梯度离心从血液中分离PBMC,并用含有6 IS的60%甲醇(MeOH)溶液提取药物。然后将细胞提取物注入HPLC系统中,并在Symmetry Shield RP18 2.1 mm x 50 mm色谱柱上分离分析物。然后通过MS / MS在电喷雾正或负电离模式下检测不同的分子,并使用多反应监测(MRM)模式记录数据。通过1 / x(2)加权二次回归,可在0.25-125 ng / ml细胞提取物的范围内构建校准曲线。获得的回归系数始终大于0.99,反算值始终位于其标称浓度的+/- 15%范围内。所有分析物的平均萃取回收率均大于80%,并且该方法精确且精确,CV和偏差低于9.4%。不同药物的定量下限(LLOQ)为0.0125至0.2 ng / ml细胞提取物。该方法已成功应用于98例接受Kaletra(R)(400/100 mg洛匹那韦/利托那韦(LPV / RTV)每天两次,n = 48)或Stocrin(R)治疗的98例HIV感染患者每天一次,每次50 mg,n = 50),并已针对2名接受Aptivus(R)治疗的患者(每天两次500 mg)进行了替普拉那韦(TPV)的细胞定量测试。 Kaletra(R)治疗的患者的LPV和RTV的平均细胞相关浓度(CC)分别为1819.0和917.2 ng / ml。用Stocrin(R)治疗的患者的平均CC值为2388.11 ng / ml,而接受Aptivus(R)的两名患者的TPV CC分别为4322.7和1078.0 ng / ml。该方法可用于分析靶组织内的抗逆转录病毒药物浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号